Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.47% | -11.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.24% | -25.34% | |||
| Operating Income | -0.24% | 25.32% | |||
| Income Before Tax | 5.63% | 57.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.63% | 57.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 508.58% | 57.61% | |||
| EBIT | -0.24% | 25.32% | |||
| EBITDA | -0.26% | 25.57% | |||
| EPS Basic | 367.04% | 57.99% | |||
| Normalized Basic EPS | -25.53% | 47.19% | |||
| EPS Diluted | 367.04% | 57.99% | |||
| Normalized Diluted EPS | -25.53% | 47.19% | |||
| Average Basic Shares Outstanding | 47.74% | 0.86% | |||
| Average Diluted Shares Outstanding | 47.74% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||